Join
Live feed
·
PRReleasevia Quantisnow
AzurRx BioPharma, Inc. logo

AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

ByQuantisnow·Wall Street's wire, on your screen.
AZRX· AzurRx BioPharma, Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZRX (AzurRx BioPharma, Inc.) and more on Quantisnow.